Q-omics provides the consensus-scored ITGA2B profile across patient tissues and cancer cell-line models. ITGA2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ITGA2B is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ITGA2B RNA expression shows 18,659 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where ITGA2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA2B survival associations across molecular data types. ITGA2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA2B RNA expression–survival associations across cancer types. High ITGA2B expression shows unfavorable associations in KIRC, ACC, UVM and LIHC, but favorable associations in HNSC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ITGA2B RNA expression.
This table summarizes ITGA2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ITGA2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA2B shows lower tumor expression in THCA, LUAD, KICH and LUSC and higher tumor expression in HNSC and CHOL. The THCA box plot shows higher ITGA2B RNA expression in normal versus tumor tissue (log2 FC = −1.210, t-test p < 0.001).
This table shows molecular features associated with ITGA2B in patient tissues and cancer cell lines. In patient samples, ITGA2B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGA2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
